[go: up one dir, main page]

ID29829A - Epotilon termodifikasi pada c-21 - Google Patents

Epotilon termodifikasi pada c-21

Info

Publication number
ID29829A
ID29829A IDW00200101797A ID20011797A ID29829A ID 29829 A ID29829 A ID 29829A ID W00200101797 A IDW00200101797 A ID W00200101797A ID 20011797 A ID20011797 A ID 20011797A ID 29829 A ID29829 A ID 29829A
Authority
ID
Indonesia
Prior art keywords
epothylons
modificated
modificated epothylons
Prior art date
Application number
IDW00200101797A
Other languages
English (en)
Indonesian (id)
Inventor
Gregory Vite
Soong Hoon Kim
Gerhard Hofle
Nicole Glaser
Thomas Leibold
Original Assignee
Bristol Myers Squibb Co
Biotech Forschung Mbh Gbf Ges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Bristol Myers Squibb Co, Biotech Forschung Mbh Gbf Ges filed Critical Bristol Myers Squibb Co
Publication of ID29829A publication Critical patent/ID29829A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
IDW00200101797A 1999-02-22 2000-02-17 Epotilon termodifikasi pada c-21 ID29829A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone

Publications (1)

Publication Number Publication Date
ID29829A true ID29829A (id) 2001-10-11

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101797A ID29829A (id) 1999-02-22 2000-02-17 Epotilon termodifikasi pada c-21

Country Status (37)

Country Link
US (1) US6262094B1 (pl)
EP (1) EP1157023B1 (pl)
JP (1) JP4598957B2 (pl)
KR (1) KR100685336B1 (pl)
CN (1) CN1205208C (pl)
AR (1) AR028815A1 (pl)
AT (1) ATE254615T1 (pl)
AU (1) AU771089B2 (pl)
BG (1) BG64987B1 (pl)
BR (1) BR0008379A (pl)
CA (1) CA2360452C (pl)
CO (1) CO5140093A1 (pl)
CZ (1) CZ301498B6 (pl)
DE (1) DE60006649T2 (pl)
DK (1) DK1157023T3 (pl)
EE (1) EE04852B1 (pl)
ES (1) ES2209831T3 (pl)
GE (1) GEP20033067B (pl)
HK (1) HK1038923B (pl)
HU (1) HUP0200076A3 (pl)
ID (1) ID29829A (pl)
IL (1) IL144501A0 (pl)
LT (1) LT4944B (pl)
LV (1) LV12755B (pl)
MX (1) MXPA01008374A (pl)
MY (1) MY120601A (pl)
NO (1) NO320806B1 (pl)
NZ (1) NZ513629A (pl)
PE (1) PE20001546A1 (pl)
PL (1) PL212545B1 (pl)
PT (1) PT1157023E (pl)
RU (1) RU2253652C2 (pl)
SK (1) SK287200B6 (pl)
TR (1) TR200102401T2 (pl)
TW (1) TWI270546B (pl)
UY (1) UY26024A1 (pl)
WO (1) WO2000050423A1 (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129558A (en) * 1996-11-18 2001-10-31 Biotechnolog Forschung Gmbh History of apothilone and pharmaceuticals and herbal preparations containing them
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
AU2001291876C1 (en) 2000-09-22 2006-11-23 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Triazolo-epothilones
AU2002213248A1 (en) * 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
JP2004522774A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
CN1610549A (zh) * 2001-02-20 2005-04-27 布里斯托尔-迈尔斯斯奎布公司 用于治疗难治肿瘤的埃坡霉素衍生物
MXPA03008135A (es) * 2001-03-14 2003-12-12 Bristol Myers Squibb Co Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
WO2003074521A1 (en) * 2002-03-01 2003-09-12 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
ATE375157T1 (de) * 2002-03-08 2007-10-15 Novartis Pharma Gmbh Kombinationspräparat aus epothilone derivate und imidazotetrazinone
EP1854464A3 (en) * 2002-03-08 2008-06-04 Novartis AG Combinations comprising epothilone derivatives and alkylating agents
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
NZ536178A (en) * 2002-05-01 2007-10-26 Novartis Ag Epothilone derivative for the treatment of hepatoma and other cancer diseases
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI291464B (en) * 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
WO2004032872A2 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo D + 5-FU/GEMCITABINE
EP1594854B1 (en) 2003-02-06 2010-09-01 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200631609A (en) * 2004-11-18 2006-09-16 Bristol Myers Squibb Co Enteric coated bead comprising ixabepilone, and preparation and administration thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
CN101360494A (zh) * 2005-11-22 2009-02-04 斯克里普斯研究学院 高效埃博霉素的化学合成
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR101506466B1 (ko) 2006-05-16 2015-03-27 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2008147941A1 (en) 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
MX2010011209A (es) * 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
AU2009255357A1 (en) * 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
EP2456790A1 (en) 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PH12012500901A1 (en) 2009-11-05 2016-08-05 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
NZ703111A (en) 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
EP2705029B1 (en) 2011-05-04 2018-10-24 Rhizen Pharmaceuticals S.A. Novel compounds as modulators of protein kinases
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AU2013239398B2 (en) 2012-03-30 2017-09-07 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5- disubstituted -3H-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of C-met protein kinases
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2016090070A1 (en) 2014-12-04 2016-06-09 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
CA2990478A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (pl)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
PT903348E (pt) 1995-11-17 2002-11-29 Biotechnolog Forschung Mbh Gbf Derivados do epotilone e sua preparacao
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
IL129558A (en) * 1996-11-18 2001-10-31 Biotechnolog Forschung Gmbh History of apothilone and pharmaceuticals and herbal preparations containing them
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
DK0975638T3 (da) 1997-02-25 2002-11-18 Biotechnolog Forschung Gmbh Sidekædemodificerede epothiloner
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
CA2286610C (en) 1997-04-18 2007-03-13 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
DE19833750A1 (de) 1997-07-16 1999-02-25 Schering Ag Thiazolderivate, Verfahren zur Herstellung und Verwendung
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
IL142938A0 (en) * 1998-12-23 2002-04-21 Bristol Myers Squibb Co Microbiological method for the preparation of an epothilone

Also Published As

Publication number Publication date
PL212545B1 (pl) 2012-10-31
TWI270546B (en) 2007-01-11
CO5140093A1 (es) 2002-03-22
LT2001086A (en) 2002-04-25
BG64987B1 (bg) 2006-11-30
JP4598957B2 (ja) 2010-12-15
IL144501A0 (en) 2002-05-23
LT4944B (lt) 2002-08-26
NZ513629A (en) 2004-01-30
CA2360452A1 (en) 2000-08-31
AU771089B2 (en) 2004-03-11
NO20014017L (no) 2001-10-17
MY120601A (en) 2005-11-30
TR200102401T2 (tr) 2001-12-21
BR0008379A (pt) 2002-09-24
CA2360452C (en) 2011-07-26
PL350179A1 (en) 2002-11-18
NO20014017D0 (no) 2001-08-17
LV12755B (lv) 2002-04-20
CN1205208C (zh) 2005-06-08
DE60006649D1 (de) 2003-12-24
RU2253652C2 (ru) 2005-06-10
KR20010102199A (ko) 2001-11-15
JP2002537395A (ja) 2002-11-05
EE04852B1 (et) 2007-06-15
HK1038923B (zh) 2004-03-19
GEP20033067B (en) 2003-09-25
CN1341114A (zh) 2002-03-20
LV12755A (en) 2001-11-20
CZ20012991A3 (cs) 2002-01-16
BG105830A (en) 2002-03-29
AU3234800A (en) 2000-09-14
PT1157023E (pt) 2004-03-31
EP1157023B1 (en) 2003-11-19
SK10782001A3 (sk) 2002-03-05
HK1038923A1 (en) 2002-04-04
ES2209831T3 (es) 2004-07-01
DE60006649T2 (de) 2004-09-30
SK287200B6 (sk) 2010-03-08
KR100685336B1 (ko) 2007-02-23
EE200100437A (et) 2002-12-16
HUP0200076A3 (en) 2003-01-28
ATE254615T1 (de) 2003-12-15
PE20001546A1 (es) 2001-03-18
HUP0200076A2 (hu) 2002-12-28
MXPA01008374A (es) 2003-06-06
NO320806B1 (no) 2006-01-30
WO2000050423A1 (en) 2000-08-31
EP1157023A1 (en) 2001-11-28
US6262094B1 (en) 2001-07-17
CZ301498B6 (cs) 2010-03-24
DK1157023T3 (da) 2004-03-29
AR028815A1 (es) 2003-05-28
UY26024A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
ID29829A (id) Epotilon termodifikasi pada c-21
DE60009395D1 (de) Bildanzeige
DE60044873D1 (de) Orientierte biopolymermembrane
NO20021411D0 (no) Organometallkatalysatorblandinger
NO20022819D0 (no) Organometallkatalysatorblandinger
NO20021243D0 (no) Brönnhåndteringssystem
DE69936399D1 (de) Aufzugsgeraet
DE60001283D1 (de) Celluloseetherfilme
NO20022106L (no) Kateterinnföringsinnretning
DE60029705D1 (de) Abtastverriegelungschaltung
DE69924240D1 (de) Ladungsträgerteilchenstrahlvorrichtung
NO20015290D0 (no) Monofluoralkylderivater
FI19992631A (fi) Radiaalimäntähydraulimoottori
FI4283U1 (fi) Höyrylaatikko
NO20021113L (no) Vitronektinreseporantagonister
FI991256A0 (fi) Apulaite tarjoilua varten
NO20020069L (no) Stigerörsystem
FI20020147A (fi) Sõhk÷sy÷tt÷jõrjestely
NO994098D0 (no) Fantaski
DE60038096D1 (de) Obreflächenwellenanordnung
FI20001519A0 (fi) Pikakartio
DE60000955D1 (de) Spurüberquerungsdiskriminator
DE60037051D1 (de) Kompositscharnier
NO20021128D0 (no) L-selektinkontrastmidler
ATA94699A (de) Anschlussanordnung